Ajooni Biotech share price target 2025, 2030: Hello friends, today in this article we will discuss another penny stock that has the potential to give you great returns. We are talking about Ajooni Biotech Limited.
Ajooni Biotech was established in the year 2010. The company manufactures cattle feed and supplements.
Ajooni Biotech overview
Ajooni Biotech Limited specializes in animal healthcare, specifically manufacturing, marketing and selling feed supplements designed to boost livestock health and productivity. Through research and development Ajooni aims to offer creative solutions which meet modern animal husbandry’s varied demands.
The company manufactures a variety of animal feed such as cattle feed, cattle feed chips, camel feed, cotton oil cake, mustard oil cake, and a wide range of feed supplements.
Ajooni Biotech frequently conducts trials to find the effectiveness of their products. The company also customises its products according to various species, breeds, and age of the animal.
Ajooni Biotech also offers technical support to the farmers, veterinarians, and other professionals. The experts of the company advise farmers or animal owners about proper dosage and usage of the product.
| About Company | Particulars |
|---|---|
| Company Name | Ajooni Biotech Ltd. |
| BSE share code | Not listed on BSE |
| NSE share code | AJOONI |
| Sector | Cattle feed and supplements |
| Headquarters | Mohali (Punjab) |
| Foundation Year | 2010 |
| Key Person | Jasjot Singh (Managing Director) |
| Market Cap | ₹ 58 Cr. |
| 52 Week high | ₹ 7.70 |
| 52 Week Low | ₹ 3.05 |
| Official Website | Ajooni Biotech website |
Ajooni Biotech share price target table
In this article, we will analyse Ajooni Biotech revenue, net profit, ratios, and other financials to conclude what will be the Ajooni Biotech share price target 2025, 2030.
If you do not want to go through our research and stock analysis, then you can refer to the table below for Ajooni Biotech share price targets.
Ajooni Biotech share price Target | 1st target | 2nd target |
|---|---|---|
| Ajooni Biotech share price Target 2024 | ₹ 8.45 | ₹ 8.97 |
| Ajooni Biotech share price Target 2025 | ₹ 11.46 | ₹ 12.23 |
| Ajooni Biotech share price Target 2030 | ₹ 18.25 | ₹ 19.55 |
Ajooni Biotech products
1. Cattle feed
The company sells Calf starter, heifer, dairy calf grower, low yield cattle, basic milking cattle, and high yield cattle under brand names viz. Diamond Wonder, Winner, Eco, Milk Booster, Heifer /grower, Nurture Calf Starter, Buff Power.
2. Feed supplements
Ajooni Biotech’s products include a range of feed supplements to improve the produce and vitality of livestock.
Probiotic Blends
Ajooni Biotech manufactures Probiotic blends to improve gut health and digestion of the animals. These blends consist of bacteria that helps absorb the nutrients better and strengthen the immune system.
Vitamin and Mineral Premixes
These premises are developed to address vitamin and mineral deficiency in animals. One example of such a premix is AUTOVITA.
Immune Boosters
Animals easily get infected by pathogens. To improve the immune system of animals Ajooni Biotech manufactures a line of supplements like LIVTUS.
Manufacturing facilities
Ajooni Biotech has 2 production facilities in Khanna with a supplement capacity of producing 1.60 Lac MTPA Cattle Feed & Feed supplements and 1 unit in Saharanpur with a Feed Supplement Capacity of 30 Lakhs LPA.
Analysis of Ajooni Biotech financial ratios
| Parameter | Value |
|---|---|
| Market Cap | ₹ 58 Cr. |
| Current Price | ₹ 6.65 |
| High / Low | ₹ 7.70 / 3.05 |
| ROCE | 6.01 % |
| ROE | 3.86 % |
| Profit after tax | ₹ 1.78 Cr. |
| Price to Earning | 32.7 |
| Debt | ₹ 3.09 Cr. |
| Sales growth | 89.4 % |
| Profit growth | 236 % |
| Industry PE | 35.7 |
| Return over 1 year | 33.0 % |
Let’s examine some financial ratios of Ajooni Biotech to understand its effectiveness of operations.
Our first stop will be their Market Cap, currently standing at Rs 58.3 Cr, making it a micro cap company; share price at the time of writing was also Rs 6.65 each.
Price-Earnings Ratio (P/E) of 32.7 and Industry P/E of 35.7 indicate that this stock may be slightly undervalued compared to peers in its industry. P/B Ratio (1.42) meets industry benchmark standards.
ROCE of 6.01% and ROE of 3.86% indicate average returns. This shows that the company is not earning high returns which might concern the long term investors. This also means that there is room for improvement in terms of operational efficiency.
The Debt-to-Equity ratio of 0.08 is very good and the company has only ₹ 3.09 Cr in Debt.
Sales Growth of 89% over one year is an impressive indicator of potential for expansion as rising product demand could lead to increased market shares over time.
Overall the financial ratios are neither too good nor too bad and the company needs to improve its ROCE and ROE.
Also Read: Laxmi organics share price target
Annual profit and loss analysis of Ajooni Biotech
| Profit & Loss | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|
| Sales | 40 | 40 | 51 | 74 | 74 | 102 |
| Expenses | 39 | 39 | 49 | 71 | 72 | 100 |
| Operating Profit | 1 | 1 | 2 | 3 | 3 | 2 |
| OPM % | 2% | 3% | 3% | 4% | 4% | 2% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 2 |
| Interest | 0 | 0 | 1 | 1 | 0 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 1 | 2 | 2 |
| Tax % | 15% | 29% | 26% | 28% | 28% | |
| Net Profit | 0 | 0 | 0 | 1 | 1 | 2 |
| EPS in Rs | 0.06 | 0.04 | 0.04 | 0.11 | 0.13 | 0.21 |
We will analyse the profit and loss of Ajooni Biotech based on the data from March 2019 to Trailing twelve months. Ajooni Biotech has shown amazing growth in this period.
Sales
When we check how well a business is operating, the first thing we usually check is the sales of the company. Ajooni Biotech’s sales numbers have been rising consistently since the last 5 years.
Company’s sales were only 40 crore in March 2019 which has risen to Rs 102 crore in Trailing twelve months.
Operating profit margins
The sales have been good but the same cannot be said about the operating profit margin which peaked in March 2021 at 4% and in the TTM it has dipped to only 2%.
As the sales doubled, the operating profit of the company has tripled from 1 crore to Rs 3 crore. However the company needs to cut down on raw material costs and marketing expenses to increase the operating profit even more.
Net profit
The company was not profitable till March 2021. In March 2022 the company reported its first annual net profit of Rs 1 crore which increased to 2 crores in March 2023. The investors will be even more attracted by the increase in EPS from Rs 0.04 in March 2019 to Rs 0.21 in the TTM.
Summary
To summarise, the sales of Ajooni Biotech is increasing at a great pace but the company needs to cut down the expenses to remain profitable.
Balance sheet comparison of Ajooni Biotech
Figures in Rs. Crores
| Balance Sheet | Mar 2022 | Mar 2023 |
|---|---|---|
| Equity Capital | 10 | 18 |
| Reserves | 6 | 24 |
| Borrowings | 5 | 5 |
| Other Liabilities | 7 | 12 |
| Total Liabilities | 29 | 59 |
| Fixed Assets | 6 | 6 |
| CWIP | 0 | 0 |
| Investments | 1 | 4 |
| Other Assets | 22 | 48 |
| Total Assets | 29 | 59 |
In this segment we will compare the company’s Balance sheet of March 2022 with March 2023 to measure the improvement or decline in equity capital, reserves, total liabilities and total assets etc.
Equity capital and reserves
The company has likely issued additional shares because the equity capital has increased from ₹10 Crore to ₹18 Crore. Another positive is that the company’s reserves have also increased from ₹6 Crore to ₹24 Crore. More reserves mean a better financial position.
Borrowings
Ajooni Biotech has not taken additional debt because the borrowings have remained stable at ₹5 Crore which also reflects in Debt-to-Equity ratio. However, other liabilities have increased from ₹7 Crore to ₹12 Crore probably due to increased payables or other financial obligations.
Total liabilities
The total liabilities have doubled from ₹29 Crore to ₹59 Crore due to increase in other liabilities and reserves.
Fixed assets
The company has not purchased any additional fixed assets which is why the fixed assets have remained constant at ₹6 Crore. Capital Work in Progress (CWIP) has emerged on the balance sheet, indicating ongoing investment in property, plant, or equipment that is not yet operational.
Overall the total assets match the total liabilities at ₹59 Crore. The increase in equity capital and reserves shows that the company is ready to expand and grow in future.
Also read: Windlas Biotech share price target
Shareholding of Ajooni Biotech
Numbers in percentages
| Shareholder | Mar 2022 | Mar 2023 | Dec 2023 |
|---|---|---|---|
| Promoters | 52.62% | 36.39% | 26.44% |
| FIIs | 0.00% | 0.01% | 0.00% |
| DIIs | 4.26% | 0.00% | 0.00% |
| Public | 43.12% | 63.59% | 73.56% |
| No. of Shareholders | 4,949 | 21,187 | 30,933 |
Shareholding trends of a company give a great idea of how well the company is doing to retain its shareholders. Let’s have a look at Ajooni Biotech’s shareholding pattern between March 2022 to Dec 2023.
Promoters
In March 2022 the promoter shareholding was 52.62% which dropped to 36.39% by March 2023 and then to 26.44% by December 2023. This is a consistent drop in promoters shareholding which shows that either promoters are losing interest or they are diluting their share for capital infusion.
FIIs and DIIs
Ajooni Biotech is not on the radar of Foreign Institutional Investors (FIIs) because their participation has been negligible in the company. Same goes for Domestic Institutional Investors who had 4.26% stake in the company in March 2022 but currently their participation is zero.
Public
Public shareholding has been increasing every year. In March 2022 the public held only 43.12% share which rose to 63.59% in 2023 and then to 73.56% by December 2023. This surge in public shareholding indicates that either the interest of the retail investors is rising or the shares sold by promoters are captured by the public.
Ajooni Biotech share price target 2024
| Ajooni Biotech share price target | 1st | 2nd |
|---|---|---|
| 2024 | ₹ 8.45 | ₹ 8.97 |
According to the sales and profit trends of Ajooni Biotech in the trailing twelve months, the company is performing very well and the same trend should continue by the end of 2024. That is why we conclude that Ajooni biotech share price target 2024 would be Rs 8.45.
Ajooni Biotech share price target 2025
| Ajooni Biotech share price target | 1st | 2nd |
|---|---|---|
| 2025 | ₹ 11.46 | ₹ 12.23 |
Ajooni Biotech can currently produce 60000 MTPA animal feed and the company is in the process of expanding the capacity by another 100000 MTPA. This should double the company’s revenue.
The share price target for Ajooni Biotech in 2025 should be at least Rs 11.46.
Ajooni Biotech share price target 2030
| Ajooni Biotech share price target | 1st | 2nd |
|---|---|---|
| 2030 | ₹ 18.25 | ₹ 19.55 |
Ajooni Biotech is situated at KHANNA which is the ASIA’s largest food grain market and cattle feed hub of India. The company has ample availability of Raw material at cheap price. That is why the company saves on the logistics cost as well. The demographic and first mover advantage will help Ajooni Biotech in the long run. That is why we estimate that Ajooni Biotech share price target would be Rs 18.25 by 2030.
Conclusion
In this post we discussed Ajooni Biotech share price target 2025, 2030. To conclude, Ajooni Biotech is a promising company with consistently rising sales. The company has been profitable for the last 2 years and the profits have been growing as well.
Ajooni Biotech has given 33% returns in the last 1 year but in the last 3 years it has given negative returns of -4.85 % return and only 1.81 % return in the last 5 years. These returns are not very lucrative for investors. However, the company has recently become profitable and the rising sales and profit numbers should result in better returns in coming years.
Remember, this is not a buy or sell recommendation but this penny stock gets a thumbs up from us.
We strongly recommend you to do your own research before investing in any company. Thank you for reading till the end.
Disclaimer: Dear Readers, please be aware that we are not associated with SEBI (Securities and Exchange Board of India). The information found on this site should only be considered educational and should not be seen as financial advice or stock recommendations. Share price predictions should only be taken as an estimate and considered valid when there are positive market signals present; any uncertainty concerning either your company or market status won't be taken into consideration in this study. Though our informational site serves educational purposes, we cannot be held liable for any financial losses you might experience as a result of using it. Instead, it serves only to keep you up to date about the stock market and financial products so you can make better investment choices - please do your own research prior to any investment decisions being made by yourself or through third parties.